Institute for OneWorld Health

The Institute for OneWorld Health was a United States nonprofit pharmaceutical research organization established in 2000 by Victoria Hale to develop and help deliver treatments for diseases that primarily affect people in low-income countries. Rather than operating as a conventional commercial drug company, it sought to combine pharmaceutical development, public-interest licensing, philanthropic funding, clinical research, and partnerships with manufacturers and public-health agencies. Its work focused on conditions for which commercial incentives were limited despite substantial disease burdens, particularly visceral leishmaniasis, malaria, and other infectious diseases. OneWorld Health’s operating model was to identify promising compounds or products, advance them through the development and regulatory process, and work with partners capable of manufacturing and distributing them affordably. A major early achievement was its work on paromomycin, an antibiotic that had been used for other purposes and was investigated as a treatment for visceral leishmaniasis. In partnership with organizations in India and elsewhere, the institute supported clinical development and regulatory work that helped establish paromomycin injection as a low-cost treatment option for the disease. This program illustrated the organization’s emphasis on adapting existing or overlooked technologies for neglected-disease settings rather than relying only on the discovery of entirely new molecules. The institute also pursued treatments for malaria. Its drug-development work contributed to efforts to stabilize the supply of artemisinin by developing a semisynthetic production route. This approach was intended to reduce dependence on the variable agricultural supply of Artemisia annua, the plant traditionally used to produce artemisinin, and to support more predictable access to artemisinin-based combination therapies. PATH later continued this work through its Drug Development program and partnerships with pharmaceutical manufacturers, including Sanofi. OneWorld Health worked across a network of universities, biotechnology companies, pharmaceutical companies, governments, foundations, and international health organizations. Its activities included laboratory research, formulation and process development, clinical trials, regulatory submissions, manufacturing partnerships, and planning for access in endemic countries. The organization’s work was particularly relevant to health systems where medicines needed to remain stable in difficult conditions, be inexpensive, and be suitable for use by health workers with limited infrastructure. The institute became affiliated with PATH and was ultimately integrated into PATH’s broader global-health structure. After the integration, its drug-development capabilities and projects were carried forward under PATH, including the organization’s work on neglected diseases and semisynthetic artemisinin. The standalone Institute for OneWorld Health therefore no longer operates as an independent organization, but its programs form part of the history of PATH’s pharmaceutical and global-health portfolio.

The Institute for OneWorld Health was founded in 2000 in the United States by Victoria Hale, a pharmaceutical scientist who sought to apply drug-development methods to diseases neglected by the commercial pharmaceutical market. Its creation reflected a growing public-health concern that many infectious diseases caused extensive illness and death in low-income countries but attracted insufficient investment because patients and health systems could not support conventional commercial pricing. The institute adopted a nonprofit development model. It looked for promising compounds and technologies, formed partnerships with academic and industrial researchers, and tried to move candidates through the stages required for practical use: toxicology, formulation, clinical trials, regulatory review, manufacturing, and distribution. Access considerations were built into the development process. The objective was not simply to demonstrate that a medicine worked, but to produce a treatment that could be manufactured at a suitable cost and delivered in countries where specialist infrastructure was limited. Its best-known program concerned visceral leishmaniasis, a parasitic disease concentrated in poorer regions and capable of causing fatal illness when untreated. OneWorld Health advanced paromomycin, an established aminoglycoside antibiotic, as a treatment for the disease. The program included clinical development in India and collaboration with local and international partners. Regulatory approval in India helped establish paromomycin injection as a treatment option, and the medicine became associated with efforts to expand access to a comparatively inexpensive therapy for visceral leishmaniasis. The organization also developed a portfolio of work relating to malaria. It supported the search for improved antimalarial medicines and pursued a semisynthetic route for producing artemisinin. Conventional artemisinin production depended heavily on crop yields and agricultural prices, creating supply uncertainty for manufacturers of artemisinin-based combination therapies. Semisynthetic production was intended to supplement botanical supplies and make the active ingredient more predictable. This work later continued after the institute joined PATH, eventually contributing to manufacturing activity conducted with Sanofi. OneWorld Health’s programs depended on collaboration rather than ownership of a large in-house manufacturing network. Partners included pharmaceutical companies, biotechnology organizations, universities, governments, philanthropic funders, and international health agencies. The institute’s role could therefore vary from scientific and clinical development to technology transfer, regulatory assistance, and preparation for deployment in endemic countries. This partnership-based structure was consistent with its nonprofit mission but also meant that progress depended on external financing, manufacturing capacity, regulatory decisions, and public-health procurement. The institute’s work attracted attention as an example of social entrepreneurship in pharmaceutical development. At the same time, public-health research associated with PATH and its partners, including an HPV-vaccine study in India, generated criticism over informed-consent procedures and research oversight. Although reported investigations linked the deaths of seven girls to causes other than the vaccine, concerns about how consent was obtained and how vulnerable participants were protected highlighted the ethical risks of conducting clinical research in disadvantaged communities. The standalone institute was eventually absorbed into PATH. Its drug-development capabilities became part of PATH’s wider programs covering drugs, vaccines, diagnostics, devices, and health-system innovation. The integration ended the institute’s independent identity but preserved the central idea behind its founding: use nonprofit and cross-sector mechanisms to develop practical, affordable interventions for diseases that conventional market incentives often leave underserved.

• 2014

  Semisynthetic artemisinin production announced

  [2]PATH (global health organization)en.wikipedia.org

  PATH and Sanofi announced the first batch of semisynthetic artemisinin after the drug-development work had moved into PATH.

• 2012

  Clinical-research controversy in India

  [2]PATH (global health organization)en.wikipedia.org

  An HPV-vaccine study associated with PATH drew official scrutiny over participant consent and research practices, although reported investigations assigned the deaths involved to other causes.

• 2011

  Integration with PATH

  [2]PATH (global health organization)en.wikipedia.org

  OneWorld Health’s programs and capabilities were incorporated into PATH’s global-health and drug-development activities.

• 2006

  Paromomycin development advances

  [1]Institute for OneWorld Healthen.wikipedia.org

  The institute’s work helped advance paromomycin injection as a treatment for visceral leishmaniasis in India.

• 2000

  Institute founded

  [1]Institute for OneWorld Healthen.wikipedia.org

  Victoria Hale established the Institute for OneWorld Health as a nonprofit organization dedicated to developing medicines for neglected diseases.

Public-interest pharmaceutical development focused on neglected diseases, affordable treatment, and access in low-resource settings.

• Antiparasitic medicine · 2006

  Paromomycin injection

  Paromomycin is an aminoglycoside antibiotic that OneWorld Health advanced for treatment of visceral leishmaniasis. The program focused on converting an existing compound into a validated, regulated, and manufacturable therapy for endemic settings, particularly India. Its importance lay in pairing clinical development with an access-oriented model intended to keep treatment affordable for patients and public-health programs.

• Antimalarial pharmaceutical technology · 2014

  Semisynthetic artemisinin

  This technology uses biological and chemical production methods to supplement plant-derived artemisinin. The objective was to reduce the supply volatility associated with agricultural production and support more reliable manufacture of artemisinin-based combination therapies. The initiative was continued by PATH and commercial partners after OneWorld Health’s integration.

• Pharmaceutical R&D services · 2000

  Neglected-disease development programs

  The institute’s broader offering was a nonprofit development platform for medicines addressing diseases with limited commercial investment. Activities included candidate selection, preclinical and clinical research, formulation, regulatory support, technology transfer, manufacturing partnerships, and planning for delivery through public-health systems.

• 2012

  HPV vaccine study consent controversy in India

  Indian authorities warned PATH after an HPV-vaccine study involving tribal girls was associated in reporting with seven deaths. Subsequent accounts attributed the deaths to unrelated causes, including illness, drowning, suicide, and an animal bite, but the study was criticized for consent procedures in which wardens or school officials reportedly signed forms for many participants. The episode raised broader concerns about research ethics, protection of vulnerable participants, and oversight in low-resource settings.

  Source

Read more

• 2011

  Integrate the institute into PATHM&A

  Background

  OneWorld Health had developed expertise in neglected-disease pharmaceutical programs, while PATH had a larger international platform spanning vaccines, drugs, diagnostics, devices, and health systems.

  Action taken

  The institute’s operations and drug-development activities were brought into PATH rather than maintained as an independent organization.

  Aftermath

  The OneWorld Health name ceased to function as a standalone operating brand, while projects such as semisynthetic artemisinin development continued under PATH.

  Source

• 2000

  Adopt a nonprofit drug-development modelStrategy

  Background

  Commercial incentives were weak for treatments aimed at diseases concentrated among low-income populations. The new organization sought to address that gap through philanthropic and partnership-based pharmaceutical development.

  Action taken

  The institute was created as a nonprofit platform combining scientific development, clinical research, regulatory work, and access planning.

  Aftermath

  The model produced programs in visceral leishmaniasis and malaria and became part of PATH’s later drug-development portfolio.

  Source

1. 1Institute for OneWorld Healthen.wikipedia.org
2. 2PATH (global health organization)en.wikipedia.org